Back to Search Start Over

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.

Authors :
Zhang, Rui
Li, Heng
Zhang, Xianglei
Li, Jian
Su, Haixia
Lu, Qiukai
Dong, Guangyu
Dou, Huixia
Fan, Chen
Gu, Zhanni
Mu, Qianwen
Tang, Wei
Xu, Yechun
Liu, Hong
Source :
European Journal of Medicinal Chemistry. Feb2021, Vol. 211, pN.PAG-N.PAG. 1p.
Publication Year :
2021

Abstract

Psoriasis is a kind of chronic inflammatory skin disorder, while the long-term use of conventional therapies for this disease are limited by severe adverse effects. Novel small molecules associated with new therapeutic mechanisms are greatly needed. It is known that phosphodiesterase 4 (PDE4) plays a central role in regulating inflammatory responses through hydrolyzing intracellular cyclic adenosine monophosphate (cAMP), making PDE4 to be an important target for the treatment of inflammatory diseases (e.g. psoriasis). In our previous work, we identified a series of novel PDE4 inhibitors with a tetrahydroisoquinoline scaffold through structure-based drug design, among which compound 1 showed moderate inhibition activity against PDE4. In this study, a series of novel tetrahydroisoquinoline derivatives were developed based on the crystal structure of PDE4D in complex with compound 1. Anti-inflammatory effects of these compounds were evaluated, and compound 36, with high safety, permeability and selectivity, exhibited significant inhibitory potency against the enzymatic activity of PDE4D and the TNF-α release from the LPS-stimulated RAW 264.7 and hPBMCs. Moreover, an in vivo study demonstrated that a topical administration of 36 achieved more significant efficacy than calcipotriol to improve the features of psoriasis-like skin inflammation. Overall, our study provides a basis for further development of tetrahydroisoquinoline-based PDE4 inhibitors against psoriasis. Image 1 • 51 tetrahydroisoquinolines derivatives as novel PDE4 inhibitors were designed, synthesized and evaluated. • The optimum compound 36 exhibited high safety, potency, permeability and selectivity in vitro. • The crystal structure of PDE4D in complex with compound 36 was solved. • Compound 36 exhibited superior therapeutic efficacy than calcipotriol against the IMQ-induced murine psoriasis-like skin inflammation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02235234
Volume :
211
Database :
Academic Search Index
Journal :
European Journal of Medicinal Chemistry
Publication Type :
Academic Journal
Accession number :
148285262
Full Text :
https://doi.org/10.1016/j.ejmech.2020.113004